Results 131 to 140 of about 10,368 (217)

Potential Dupilumab-Induced Unmasking of Specific Immunoglobulin Deficiency: A First-of-Its-Kind Case. [PDF]

Case Rep Pulmonol
Bista R, Sathya DA, Gupta S, Thameem D.
europepmc   +1 more source

Impact of Dupilumab and Upadacitinib Treatment on Epigenetic and Transcriptomic Alterations in Skin‐Homing T Cells of Atopic Dermatitis Patients

Clinical &Experimental Allergy, EarlyView.
Ahmed M. I. Elfiky, Hidde M. Smits, Marlot van der Wal, Coco Dekkers, Celeste M. Boesjes, Julia Drylewicz, Marjolein de Bruin‐Weller, Femke van Wijk   +7 more
wiley   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). [PDF]

Dermatol Ther (Heidelb)
Potestio L, Patruno C, Ferrucci SM, Narcisi A, Ortoncelli M, Pezzolo E, Malagoli P, Girolomoni G, Guanti MB, Rossi M, Carugno A, Gola M, Satolli F, Loconsole F, Manzo Margiotta F, Balato A, Nettis E, Burroni AG, Rongioletti F, Savoia P, Veronese F, Dal Bello G, Paolino G, Esposito M, Legori A, Campanati A, Barei F, Zussino M, Gargiulo L, Bianco M, Ingurgio RC, Gaiani F, Maurelli M, Zerbinati N, Mercuri SR, Italian AD-Landscape Group, Ribero S, di Vico F, Napolitano M.   +38 more
europepmc   +1 more source

Large‐scale meta‐analysis of infection risk with JAK–STAT inhibitors in 29,000 patients

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this large meta‐analysis of 74 randomized controlled trials involving more than 29,000 patients, JAK–STAT inhibitors were associated with an increased risk of influenza, bronchitis and herpes infections, particularly herpes zoster, while an increased risk of serious opportunistic or fungal infections was not observed.
Máté Krebs, Lili Gulyás, Karen Krisztina Fazekas, Benedek Nagy, Mária Veronika Kolonics, Fanni Adél Meznerics, Norbert Kiss, András Bánvölgyi, Péter Hegyi, Péter Holló, Lajos Vince Kemény   +10 more
wiley   +1 more source

Association of Skin Dryness and Disease-related Parameters with Mechanical Alloknesis in Atopic Dermatitis: A Crosssectional and Prospective Cohort Study. [PDF]

Acta Derm Venereol
Uto M, Komiya E, Kojima G, Kamata Y, Toyama S, Honda K, Kaneko T, Suga Y, Tominaga M, Takamori K.   +9 more
europepmc   +1 more source

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot   +17 more
wiley   +1 more source

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation. [PDF]

Allergol Select
Werfel T, Heratizadeh A, Augustin M, Bangert C, Bauer A, Biedermann T, Brans R, Domröse N, Gieler U, Gießler-Fichtner O, Hamelmann E, Hampe S, Heuer R, Kahle J, Kinberger M, Koch M, Köhler M, Legat F, Nemat K, Neustädter I, Peters EMJ, Radonjic-Hoesli S, Reese I, Schmid-Grendelmeier P, Schmidt-Göhrich UK, Schmitt J, Schnopp C, Schwennesen T, Simon D, Stamos K, Termeer C, Treudler R, von Kiedrowski R, Wagner I, Waßmann-Otto A, Weckmann G, Werner RN, Wollenberg A, Worm M, Ott H.   +39 more
europepmc   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source

The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia. [PDF]

Clinicoecon Outcomes Res
Abu-Shraie N, Al-Sheikh A, Alharbi I, Alanizy L, Alshraim M, Khoshhal SI, AlSalman SA, Alrumaih A, Fasseeh AN, Elezbawy B, Abaza N, Semida A, George M, Amin S, Binamer Y.   +14 more
europepmc   +1 more source